Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study Authors: Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduardo Durán Ferreras, Rosario Blasco Quílez, Jose Meca-Lallana, Lamberto Landete Pascual, Yolanda Aladro-Benito, Sabas Boyero Durán, Julia Gracia Gil, Ana Belén Caminero Rodríguez, Antonio Tomás Cano Orgaz, Sara Eichau Madueño, María Rosa Querol Pascual, María Otano Martínez, Ana María Alonso Torres, Carmen Calles Hernández, Ana López Real, Adrián Ares Luque, Jose Ramón Lorenzo González, Lidia Gómez Vicente, María Díaz Sánchez Published: 2026 ABSTRACT AbstractBackground:Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.Objective:To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.Design:Non-interventional/observational, retrospective, multicenter study (28 centers).Methods:Patients (⩾18 years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24 months before and 12 months after siponimod treatment.Results:In total, 210 participants were included (mean age: 52.5 ± 8.6 years; females: 71.0%). At treatment initiation, the mean Expanded Disability Status Scale (EDSS) score was 5.7 ± 1.2. The mean time since multiple sclerosis diagnosis and the median time since active SPMS diagnosis were 16.7 ± 8.9 years and 1.3 (0.3; 4.4) years, respectively. Common comorbidities included psychiatric disorders and dyslipidemia (20.6%, each). Regarding working status, 55.9% with available information showed incapacity for work. Prior to siponimod, 44.3% received highly effective therapies: fingolimod (20.5%), rituximab (9.5%), ocrelizumab (5.2%), natalizumab (4.8%), and alemtuzumab (2.4%). After 1 year, 82.8% of the patients remained stable in terms of disability progression, 94.3% were free of relapses, and 85.7% did not present radiological disease activity; 46.2% experienced adverse events, 8.6% experienced serious adverse events, and 26 (12.4%) patients discontinued permanently.Conclusion:In the study cohort, pwSPMS had high disability scores and comorbidities; more than half were unable to work, and over 40% had previously received high-efficacy therapies. After 1 year of siponimod treatment, most pwSPMS showed no signs of disease activity, with stabilized EDSS scores and relapses and new T2 or gadolinium-T1 lesions, as well as a favorable safety profile.Keywords: real-world, siponimod, Spain, SPMS Introduction Multiple sclerosis (MS) is an inflammatory, demyelinating, degenerative disease of the central nervous system characterized by relapses with or without residual worsening and/or steady progression, independent of relapses. 1 MS is mainly classified into three types: relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), and primary progressive MS. 1 Recurrent forms are characterized by the appearance of relapses, defined as acute or subacute episodes of new or increasing neurological dysfunction, followed by total or partial recovery, in the absence of fever or infection. 1 Progressive forms are characterized by clinical evidence of disease progression, regardless of relapses, and may remain stable over time. 1 SPMS can be further classified as non-active or active, depending on whether patients continue to experience relapses and/or radiological activity. 1 The therapeutic strategy in active SPMS is to reduce the risk of relapses and disability progression through disease-modifying treatment (DMT). 2 The evolution from RRMS to SPMS represents a critical point in the disease, since it indicates an unyielding progression of disability, as available treatments are not capable of stopping disease progression. 3 The risk and timing involved in the transition from RRMS to SPMS remain largely unpredictable due to the unavailability of suitable immunologic, clinical, and imaging predictive markers. 1 PANGAEA 2.0, a real-world evidence (RWE) German study including people with SPMS (pwSPMS), has been carried out to establish more accurate, unified diagnostic criteria for detecting SPMS. 4 Siponimod, a selective sphingosine 1-phosphate receptor modulator, is approved for active SPMS treatment in the European Union. 5 The Spanish Agency of Medicines and Medical Products recommends siponimod as first-line treatment for active SPMS, together with interferon beta 1b. 6 Ponesimod, cladribine, ofatumumab, ocrelizumab, and ublituximab are reimbursed for relapsing MS, including patients with SPMS who experience relapses. In the phase III randomized EXPAND clinical trial and its post hoc analysis,7,8 siponimod reduced the risk of disability progression more than placebo in pwSPMS.9,10 There are limited RWE data on new DMTs such as siponimod in pwSPMS. Therefore, the objective of the current study was to assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting. Methods Study design and participants This was a non-interventional, observational, retrospective, multicenter study conducted in 28 hospitals in Spain among pwSPMS under routine clinical practice. Patients underwent clinical assessments and received standard routine medical care, as determined by their treating physician(s). Data were obtained from a secondary data source, that is, electronic medical records from hospitals. Pseudonymized patient data were collected and documented in electronic case report forms. The inclusion criteria were: (i) pwSPMS, as diagnosed by a physician, who received at least 1 dose of siponimod treatment for SPMS within an observation period of 12 months (during the drug initiation period between April 2021 to 01 September 2022); (ii) patients aged ⩾18 years at the time of siponimod treatment initiation; and (iii) availability of the data for at least 12 months after siponimod initiation. The exclusion criteria were: (i) patients with any contraindication to siponimod, according to applicable summary of product characteristics; and (ii) patients participating in any clinical trial at any time during the study period. Study outcomes The primary outcomes were demographics (age, sex, and working status) and clinical characteristics (Expanded Disability Status Scale (EDSS) score at start of treatment; years since MS diagnosis; years since SPMS diagnosis; relapses; radiological disease activity; patients’ cytochrome P450 family 2 subfamily C member 9 (CYP2C9) genotype; comorbidities; and previous DMT). The secondary outcomes were treatment patterns (siponimod dose, dose modification, concomitant treatment administered, discontinuation of siponimod, and reasons for discontinuation of siponimod), safety (adverse events (AEs), serious adverse events (SAEs), and change in lymphocyte count from baseline), and effectiveness (confirmed disability progression (CDP), time to first relapse, and radiological disease activity (new and/or enlarging T2 lesion and new gadolinium-T1 lesions by magnetic resonance imaging), and annualized relapse rate). CDP was determined by an increase of ⩾1 point in the EDSS score if the baseline EDSS was ⩽5.5 or an increase of 0.5 points if the baseline EDSS score was >5.5, confirmed at a second visit performed at least 3 months later. Exploratory outcomes included safety (AEs, SAEs, discontinuation) of siponimod by EDSS score (patients with EDSS score >6.5 and patients with EDSS score ⩽6.5) and by age (patients aged >60 years and patients aged ⩽60 years); grade 4 lymphopenia and infections as AEs in patients previously treated and not treated with DMTs; and correlation analysis between infectious events and lymphopenia grade at baseline, 6 months, and 12 months. Statistical analysis The study sample size should allow the estimation of dichotomous and continuous variables. The required sample size has been calculated to estimate dichotomous variables (assuming maximum uncertainty 50/50 for each category) with a precision of 0.060–0.075 (6.0%–7.5%) and with a confidence level of 95%. In addition, the sample size required to estimate continuous variables with a precision of ±0.12 to ±0.15 units around the mean, assuming a standard deviation (SD) of 1 and with a significance level of 0.05 has also been calculated. It is assumed that dropouts could be about 10%. According to this data, it is recommended that approximately 245 SPMS patients should be recruited; this would maintain a significance level of 0.05 for all analyses and yield precisions close to 6.6% and 0.132 units for dichotomous and continuous variables, respectively. The data were analyzed descriptively. Continuous variables were reported as means with SD or medians with interquartile ranges (IQRs). Categorical variables were summarized as numbers and proportions. No imputation of missing data was carried out. Fisher’s Exact Test was used to evaluate statistically significant differences between subgroups. Kendall Tau correlation coefficient was used for correlation analysis. p-Values ⩽ 0.05 were considered statistically significant. The annualized relapse rate was estimated using a generalized linear mixed model using relapse data from the 12-month pre-treatment period. Ethical considerations Patient recruitment adhered to the strict inclusion and exclusion criteria, as well as following Good Pharmacoepidemiology Practices and the ethical principles outlined in the Declaration of Helsinki. The current study was approved by the Research Ethics Committee of Hospital Clínico San Carlos (22/474-O_M_NoSP) on July 21, 2022. In accordance with applicable ethical standards, the requirement for informed consent was waived by the Ethics Committee due to the retrospective, non-interventional nature of the study and the use of pseudonymized data extracted from electronic medical records. The study involves minimal risk to participants, and obtaining consent was considered not reasonably practicable and would have imposed a disproportionate burden on patients with SPMS, as it would have required additional study‑related visits solely for consent purposes, potentially affecting participation and introducing selection bias. The waiver was granted in compliance with Regulation (EU) 2016/679 (GDPR) and Organic Law 3/2018 (LOPDGDD), ensuring full protection of personal data and confidentiality. Results Primary outcomes Demographic and clinical characteristics A total of 210 pwSPMS treated with siponimod were included in the study analysis. The mean age of 210 siponimod users with SPMS was 52.5 ± 8.6 years. The majority of the patients were female (71.0%, n = 149). Of note, 55.9% (n = 71) with available information on working status showed incapacity for work. The mean baseline EDSS score (n = 207) was 5.7 ± 1.2. Most patients had been diagnosed with MS over 17 years before being enrolled in the study (mean time since MS diagnosis, 16.7 ± 8.9 years, n = 204). The median (IQR) time since SPMS diagnosis for 210 patients was 1.3 (0.3; 4.4) years. About 39.0% (n = 78) and 29.7% (n = 62) of the patients experienced 1 or more MS relapses during the 24 and 12 months prior to the start of siponimod treatment, respectively. The percentage of patients with 1 or more gadolinium-T1 lesions during the 24 months prior to the start of siponimod treatment was 20.3% (n = 37), and 1 or more new or enlarged T2 lesions during the 24 months prior to the start of siponimod treatment were present in 54.1% (n = 106) of the patients (Table 1). Table 1.Demographic and clinical characteristics at baseline.VariableMeasure/categoryTotal (N = 210) a Demographic characteristics Age, yearsMean (SD)52.5 (8.6) Sex, n (%)Female149 (71.0%) Working status, n (%)Full-time17 (13.4%)Part-time3 (2.4%)Retired20 (15.7%)Incapacity for work71 (55.9%)Medical leave7 (5.5%)Unemployed9 (7.1%)Unknown or missing83Valid n209Clinical characteristics CYP2C9 genotype, n (%)CYP2C9*1*1117 (55.7%)CYP2C9*1*251 (24.3%)CYP2C9*1*328 (13.3%)CYP2C9*2*27 (3.3%)CYP2C9*2*32 (1.0%)Other b 5 (2.4%) Time since MS diagnosis, (years)Mean (SD)16.7 (8.9)Valid n204 Time since SPMS diagnosis, (years)Mean (SD)4.0 (5.8) Relapses in the last 24 months prior to the start of treatment, n (%)Yes78 (39.0%)Valid n200 Relapses in the last 12 months prior to the start of siponimod treatment, n (%)Yes62 (29.7%)Valid n209 Gadolinium-T1 lesions 24 months prior to the start of siponimod treatment, n (%)Yes37 (20.3%)Valid n182 New/enlarged T2 lesions 24 months prior to the start of siponimod treatment, n (%)Yes106 (54.1%)Valid n196 Baseline EDSS score at the start of siponimod treatmentMean (SD)5.7 (1.2)Valid n207 SDMT scoreMean (SD)20.9 (13.2)Valid n14 Comorbidities c n (%)Psychiatric disorders41 (20.6%)Dyslipidemia41 (20.6%)Urinary disease39 (19.6%)Hypertension36 (18.1%)Other neurologic diseases28 (14.1%)Osteomuscular and conjunctive tissue disease24 (12.1%)Thyroid-related disorders22 (11.1%)No comorbidities48 (24.1%)Valid n199aUnless other information is reflected.bIncludes one case with a CYP2C9*3 genotype out of the five subjects in whom only the presence of CYP2C9*3 was assessed.cOnly comorbidities that affect more than 10% of the patients are included in the table.CYP2C9, cytochrome P450 family 2 subfamily C member 9; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; n, number of patients; N, total number of patients included in analysis; SD, standard deviation; SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive multiple sclerosis. Demographic and clinical characteristics at baseline. Unless other information is reflected. Includes one case with a CYP2C9*3 genotype out of the five subjects in whom only the presence of CYP2C9*3 was assessed. Only comorbidities that affect more than 10% of the patients are included in the table. CYP2C9, cytochrome P450 family 2 subfamily C member 9; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; n, number of patients; N, total number of patients included in analysis; SD, standard deviation; SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive multiple sclerosis. Prior to starting siponimod, the most common DMT received by patients was fingolimod (20.5%, n = 43), and 7.6% (n = 16) of the patients did not receive any DMT previously. About 44.3% of the patients had received highly effective therapies prior to siponimod initiation: fingolimod (20.5%, n = 43; median washout period 14 days (IQR 1–32 days)), rituximab (9.5%, n = 20), ocrelizumab (5.2%, n = 11; median washout period 225 days (IQR 120–364 days)), natalizumab (4.8%, n = 10), alemtuzumab (2.4%, n = 5; mean washout period 158 days (IQR 0–474 days)), and cladribine (1.9%, n = 4; median washout period 370 days (IQR 171–425 days); Figure 1). Last treatment before siponimod initiation. *Includes: interferon beta 1a subcutaneous 22 µg; interferon beta 1a subcutaneous 44 µg; interferon beta 1a intramuscular; interferon beta 1b subcutaneous; and peginterferon beta 1a. **Azathioprine (n = 3), Evobrutinib (n = 1), Mitoxantrone (n = 1). HET, highly effective therapies; MET, moderately effective therapies. The most common genotypes among patients were the CYP2C9 allele *1*1 (CYP2C9*1*1) genotype (55.7%, n = 117), followed by the CYP2C9 allele *1*2 (CYP2C9*1*2) genotype (24.3%, n = 51) and the CYP2C9 allele *1*3 (CYP2C9*1*3) genotype (13.3%, n = 28). In terms of comorbidities, psychiatric disorders, dyslipidemia, urinary disease, and hypertension were present in 20.6% (n = 41), 20.6% (n = 41), 19.6% (n = 39), and 18.1% (n = 36) of patients, respectively. Neurologic diseases other than MS were reported in 14.1% (n = 28) of the patients (Table 1). Secondary outcomes Treatment patterns The majority of patients (85.2%, n = 173) received a 2-mg maintenance siponimod dose. Subsequent dose modification was needed in only 12.4% (n = 26) of patients, with the most relevant reasons being lymphopenia (80.8%, n = 21), followed by elevated hepatic enzymes (15.4%, n = 4). During the study, 79.0% (n = 166) of the patients used concomitant treatment (Table S1). About 18.1% (n = 38) of the patients discontinued siponimod treatment during the study period. Permanent discontinuations of siponimod were reported in 26 (12.4%) patients and temporary interruptions in 14 (6.7%) patients. 42.3% (n = 11) of the patients who permanently discontinued siponimod did not switch to another DMT during the study period. Among patients who permanently discontinued and switched, rituximab was the most common DMT treatment (46.7%; n = 7). These categories are mutually exclusive. AEs constituted the most common reason for temporary interruptions (85.7%, n = 12) and permanent discontinuations (69.2%, n = 18; Figure 2). Discontinuation of siponimod treatment and reasons for discontinuation. *One patient had two temporal discontinuations and one permanent discontinuation; this is why the percentages exceed 100%. Safety During the study period, AEs were reported in 46.2% (n = 97) of patients. Reported AEs included, among others, infections (12.4%, n = 26), grade 4 lymphopenia (9.5%, n = 20), and elevation of hepatic enzymes (5.2%, n = 11). SAEs were reported in 8.6% (n = 18) of patients. Regarding treatment discontinuations, 18.6% (n = 18) and 16.5% (n = 16) of patients had AEs, leading to temporary discontinuation and permanent discontinuation, respectively. Moreover, among the patients that experienced SAEs (N = 18), there were 27.8% patients with SAEs leading to permanent, and, also, 27.8% temporal discontinuations. There were no deaths reported during the observation period (Table 2). Table 2.AEs and SAEs.VariableMeasureTotal (N = 210)Patients with AEs, n (%)Yes97 (46.2%)Patients with AEs of special interest, n (%)Infections26 (12.4%)Lymphopenia20 (9.5%)Hepatic enzymes elevation11 (5.2%)Hypertension6 (2.9%)COVID-196 (2.9%)Bradyarrhythmia3 (1.4%)Epileptic seizure3 (1.4%)Macular edema2 (1.0%)Cutaneous neoplasia1 (0.5%)Other51 (24.3%)Patients with SAEs, n (%)Yes18 (8.6%)Patients with AEs leading to permanent discontinuation, n (%)Yes16 (16.5%)Valid n97Type of AEs leading to permanent discontinuation, n (%)Lymphopenia3 (18.8%)Macular edema2 (12.5%)Bradyarrhythmia2 (12.5%)Elevated hepatic enzymes2 (12.5%)Infection2 (12.5%)Hypertension1 (6.3%)Epileptic seizure1 (6.3%)Asthenia1 (6.3%)Headache1 (6.3%)Limbs’ edema1 (6.3%)Nausea1 (6.3%)Valid n16Patients with AEs leading to temporary discontinuation or dose adjustment, n (%)Yes18 (18.6%)Valid n97Patients with SAEs leading to permanent discontinuation, n (%)Yes5 (27.8%)Valid n18Type of SAEs leading to permanent discontinuation, n (%)Epileptic seizure2 (40.0%)Lymphopenia1 (20.0%)Hypertension1 (20.0%)Hyponatremia1 (20.0%)Breast ductal cancer infiltrating1 (20.0%)Valid n5Patients with SAEs leading to temporary discontinuation or dose adjustment, n (%)Yes5 (27.8%)Valid n18Patients who died, n (%)Yes0 (0.0%)AE, adverse event; COVID-19, coronavirus disease 2019; n, number of patients; N, total number of patients included in analysis; SAE, serious adverse event. AEs and SAEs. AE, adverse event; COVID-19, coronavirus disease 2019; n, number of patients; N, total number of patients included in analysis; SAE, serious adverse event. The median lymphocyte count was 1610 mm3 at baseline (n = 204), while it was 460 mm3 at 12 months follow-up (n = 176), showing a reduction of 71.4% from baseline. Most patients had a normal lymphocyte count (81.4%, n = 166) at baseline. The point prevalence of grade 4 lymphopenia remained stable and low throughout the follow-up period, with rates of 2.1% (n = 4) and 1.7% (n = 3) at 6 and 12 months, respectively (Table S2). Effectiveness In terms of disability progression, among the 186 patients who had this information available, 154 (82.8%) patients remained stable after 1 year following siponimod initiation, and 17.2% (n = 32) presented 3-month CDP. About 94.3% (n = 197) of the patients were free from relapses 12 months after siponimod initiation. The annualized relapse rate for the period prior to siponimod treatment was 0.31 annual relapses per person, and for the period after siponimod treatment, it was 0.06 annual relapses per person. The mean time to first relapse for 12 patients was 4.9 ± 3.9 months. The results of the generalized linear mixed model for annualized relapse rates showed that siponimod initiation was associated with 5 times lower annualized relapse rates compared with rates before siponimod initiation (incidence rate ratio, 0.20; 95% CI, 0.11–0.37). Radiological disease activity was detected in 14.3% (n = 16) of the patients. Specifically, new gadolinium-T1 lesions were identified in 4.3% (n = 4) of the patients, whereas new or enlarging T2 lesions were found in 12.5% (n = 14) of the patients (Table S3). Exploratory outcomes No statistically significant differences were found regarding safety in special population groups, specifically those with EDSS scores >6.5 and patients over 60 years old (Tables S4 and S5). Similarly, no statistically significant association was found between the development of grade 4 lymphopenia and prior fingolimod exposure, nor between infections rates and pre-treatment with fingolimod or pre-treatment with anti-CD20 therapies. Finally, infections showed no significant correlation with a lymphopenia grade at baseline (p = 0.87), 6 months (p = 0.18), and 12 months (p = 0.25). Discussion SPMS poses a challenge for existing registries and RWE initiatives, as pwSPMS might be underrepresented due to late diagnosis and silent disease progression. The current study focused on the real-world use of siponimod. The effectiveness and safety of siponimod have been evaluated previously in the pivotal EXPAND trial 7 and its post hoc analyses.8,11 Demographic and baseline characteristics of patients were found to differ slightly between the EXPAND trial 7 and recent real-world studies,12 –17 including the current study. In comparison with the active subgroup of the EXPAND trial, 11 patients in the current study were older (mean age 52.5 vs 46.2 years, respectively). The current study also had a higher percentage of women (71.0% and 64%, 11 respectively), a longer time since diagnosis of MS (16.7 vs 11.7 years 11 ), a longer time since conversion to SPMS (4.0 vs 3.2 years 11 ), and relatively similar baseline EDSS scores (5.7 vs 5.5 11 ). These findings align with recent real-world studies, which also reported differences in demographics and clinical characteristics compared with the EXPAND trial.12 –17 These real-world studies showed an age range of 51–55 years,12 –14,16,17 a predominantly female patient population,12,14,16,17 a duration since a diagnosis of MS of 15–17 years,12,16,17 baseline EDSS scores of 4.6–5.2,15 –17 and CYP2C9*1*1 to be the common genotype.12,13 The delayed diagnosis of SPMS might be due to challenges in measuring disease progression in clinical practice. 18 A formal consensus method could be employed to make feasible recommendations for timely, accurate identification of disease progression. 18 There is no specific tool to detect progression early. Regarding the disease burden, it is important to highlight that most patients included were not actively working; further, 13.4% were full-time and 2.4% were part-time employees. In fact, 55.9% of the patients reported incapacity for working. These data evidence the pronounced economic and family burden associated with SPMS. Psychiatric comorbidities were frequent in our cohort, with depression being the most common psychiatric condition. Prevalence estimates for depression among people with MS are higher compared with the general population. 19 Considering pwSPMS tend to show higher levels of disability than people in general with MS, a higher prevalence of depression would be expected among study participants. On the other hand, the high prevalence of psychiatric comorbidities highlights the optimization of psychiatric care as a potential area for improving the outcomes of pwSPMS. 20 Other comorbidities, such as hypertension and urinary complications, were also observed in our study, which can significantly affect the quality of life, in line with previous literature.13,21 –23 It is important to highlight that most patients (92.4%) received other DMTs before siponimod initiation, indicating that the number of naïve pwSPMS was low, which aligns well with other real-world studies showing a lower percentage of treatment-naïve patients.12,13,15 –17 Moreover, fingolimod was the most common DMT received prior to siponimod, which aligns with other real-world studies also showing fingolimod to be the most common DMT prior to siponimod initiation.12 –14 Both fingolimod and siponimod are functional antagonists of the receptor in the sphingosine 1-phosphate pathway and produce an important anti-inflammatory effect during the active phases of MS. Switching from fingolimod to siponimod was shown to be cost-effective and clinically advantageous, especially in the context of SPMS. 24 It should be considered that most patients in the study received fingolimod previously, and they seemed to show a therapeutic response during the 12 months follow-up period following the initiation of siponimod. Fingolimod’s longer half-life leads to prolonged drug exposure, complicating side effects management and treatment adjustments. 25 Compared with fingolimod, siponimod has a shorter half-life; therefore, drug effects wear off rapidly after discontinuation. 26 Siponimod selectively binds to sphingosine 1 phosphate receptor 1 and sphingosine 1 phosphate receptor 5. 24 Shorter half-life and receptor selectivity contribute to the favorable safety profile of siponimod. 26 Genetic variants in CYP2C9 can affect the metabolism of siponimod; therefore, it is important to consider genotyping when prescribing siponimod. 7 In the current study, the AE rate (46.2%) is comparable with that reported in a previous real-world study (47.9%). 12 However, a higher AE rate was observed in the AMASIA study with 3 years of follow-up (AEs in 83.3%, SAEs in 49.5%, and death in 0.5%). 16 Lymphopenia was the most common AE reported in 35.8%–38.1% of the patients over 18 months to 3 years of follow-up in previous real-world studies, but grade 4 lymphopenia was specifically assessed only in a few specific cases.12,16 Within this cohort, grade 4 lymphopenia was reported in 9.5% of patients at any time during follow-up. Other real-world studies showed the rate of grade 4 lymphopenia to be 8.5% 1–3 months after siponimod treatment.13,14 Permanent discontinuation due to AEs was noted in 16.5% of patients in the present analysis, whereas in the EXPAND core and extension trial, 27 11.8% of the patients discontinued treatment due to AEs. In this real-world study, 70.3% of the patients were free from relapse during the year before siponimod initiation and 94.3% during the year afterward. The results on the rates of relapse concurred with radiological observations before and after siponimod initiation, with new gadolinium-T1 lesions being observed in only 4.3% of the patients and new/enlarging T2 lesions in 12.5%. These findings corroborate other real-world studies showing a relapse rate of 7.4% over 18 months 12 and a reduction in the annualized relapse rate from 60% at baseline to 12% at the end of 1 year of follow-up. 15 Additionally, 17.2% of the population had 3-month CDP after treatment initiation. Moreover, as mentioned above, 82.8% of the patients remained stable in terms of disability progression, which is consistent with previous studies.12,15 This delay in the progression of disability might be attributed to the multifaceted mechanisms of action of siponimod—potentially addressing both the inflammatory aspects of MS and exerting neuroprotective effects. This dual action could have contributed to the efficacy of siponimod in preserving neurological function in pwSPMS. The current study had some limitations. In any study based on secondary data, the accuracy of the analyses depends on the correctness of the information available in the data sources. To minimize the risk of including inaccurate information, all retrieved data were reviewed for possible inconsistencies or implausible information. There is no universal definition of SPMS disease. 28 Thus, the diagnosis of SPMS is not standardized. This may be a limitation when generalizing the results. It is important to point out that the lack of a universal definition and the absence of effective treatments for these patients may delay the diagnosis of SPMS. The study duration of 12 months was possibly too short to evaluate the time to progression, especially in higher EDSS scores, as previously seen in several studies.29 –31 Finally, the results regarding the annualized relapse rate must be interpreted with caution. Since no comparator group was considered, it is difficult to assess whether any changes in the outcome are due to siponimod or confounding factors (such as the natural disease course). 32 Nonetheless, in an attempt to minimize bias, several covariates were considered for adjustment in the generalized linear mixed model, with a data-driven strategy adopted for covariate selection. Conclusion The RESYZE study has further strengthened the growing body of evidence supporting the use of siponimod in the management of active SPMS. The study describes the clinical profile of pwSPMS treated with siponimod in the Spanish population. Compared with the active subgroup in the EXPAND trial, patients were older and had a longer disease history. Nearly two-thirds were retired or unable to work, and most had previously received highly effective therapies. After 12 months of treatment, most patients showed no evidence of disease activity, with stabilization in EDSS scores, relapses, and new T2 or gadolinium-T1 lesions. The safety profile was favorable, with low rates of grade 4 lymphopenia, SAEs, and infections unrelated to lymphopenia levels. These findings support effectiveness and safety of siponimod in maintaining disease stability in routine clinical practice and provide valuable insights into its performance outside of controlled trial settings and as a treatment option for individuals with active SPMS. Future research should continue to build on these results, exploring new avenues such as focusing on patient-centered outcomes, such as quality of life and functional status, to ensure that treatments align with patient priorities and needs. Supplemental Material sj-docx-1-tan-10.1177_17562864261472650 – Supplemental material for Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study Supplemental material, sj-docx-1-tan-10.1177_17562864261472650 for Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study by Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduardo Durán Ferreras, Rosario Blasco Quílez, Jose Meca-Lallana, Lamberto Landete Pascual, Yolanda Aladro-Benito, Sabas Boyero Durán, Julia Gracia Gil, Ana Belén Caminero Rodríguez, Antonio Tomás Cano Orgaz, Sara Eichau Madueño, María Rosa Querol Pascual, María Otano Martínez, Ana María Alonso Torres, Carmen Calles Hernández, Ana López Real, Adrián Ares Luque, Jose Ramón Lorenzo González, Lidia Gómez Vicente and María Díaz Sánchez in Therapeutic Advances in Neurological Disorders Acknowledgments We thank IQVIA (Carmen Barrull, María Lloret, and Geetika Nirmal) for providing medical editorial assistance with this manuscript. Footnotes ORCID iDs: Celia Oreja-Guevara https://orcid.org/0000-0002-9221-5716 Jose Meca-Lallana https://orcid.org/0000-0001-5050-9890 Ana María Alonso Torres https://orcid.org/0000-0002-7337-8384 Supplemental material: Supplemental material for this article is available online. Contributor Information Celia Oreja-Guevara, CSUR Multiple Sclerosis, Department of Neurology, Hospital Universitario Clínico San Carlos, IdISCC, Madrid, Spain; Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. Irene Gómez-Estévez, CSUR Multiple Sclerosis, Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain. Laura Agüado García, Neurology Department, Hospital Universitario de Burgos, Burgos, Spain. Jesus Martín Martínez, CSUR Esclerosis Multiple, Neurology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. Montserrat Gómez Gutiérrez, Neurology Department, Hospital Universitario de Cáceres, Cáceres, Spain. Francisco Gascón Giménez, Neurology Department, Hospital Clínico de Valencia, Valencia, Spain. Eduardo Agüera Morales, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. Virginia Meca-Lallana, Neurology Department, Hospital Universitario de La Princesa, Madrid, Spain. Francisco Javier Barrero Hernández, Neurology Department, Instituto Investigación Biosanitaria, Hospital Universitario Clínico San Cecilio, Granada, Spain. Vicente González Quintanilla, Neurology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Lucía Romero Pinel, Neurology Department, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. Virginia Delgado Gil, Neurology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Eduardo Durán Ferreras, Neurology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Rosario Blasco Quílez, Neuroimmunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain. Jose Meca-Lallana, Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit, Neurology Department, Virgen de la Arrixaca Clinical University Hospital (IMIB-Arrixaca) and NICEM Cathedra-UCAM-San Antonio Catholic University, Murcia, Spain. Lamberto Landete Pascual, Neurology Department, Hospital Universitario Dr. Peset, Valencia, Spain. Yolanda Aladro-Benito, Neurology Department, Hospital Universitario de Getafe, Getafe, Spain; Instituto Investigación IdiPAZ, Universidad Europea de Madrid, Madrid, Spain. Sabas Boyero Durán, Neurology Department, Hospital Universitario de Cruces, Barakaldo, Spain. Julia Gracia Gil, Neurology Department, Hospital General Universitario de Albacete, Albacete, Spain. Ana Belén Caminero Rodríguez, Neurology Department, Complejo Hospitalario de Ávila, Ávila, Spain. Antonio Tomás Cano Orgaz, Neurology Department, Hospital de Mataró, Mataró, Spain. Sara Eichau Madueño, Neurology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. María Rosa Querol Pascual, Neurology Department, Hospital Universitario de Badajoz, Badajoz, Spain. María Otano Martínez, Neurology Department, Hospital Universitario de Navarra, Pamplona, Spain. Ana María Alonso Torres, Neurology Department, Hospital Regional Universitario de Málaga, Málaga, Spain. Carmen Calles Hernández, Neurology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain. Ana López Real, Neurology Department, Complejo Hospitalario Universitario de A Coruña, La Coruña, Spain. Adrián Ares Luque, Neurology Department, Complejo Asistencial Universitario de León, León, Spain. Jose Ramón Lorenzo González, Neurology Department, Hospital Ribeira Povisa, Vigo, Spain. Lidia Gómez Vicente, Medical Department, Novartis Farmacéutica, S.A., Barcelona, Spain. María Díaz Sánchez, Neurology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Declarations Ethics approval and consent to participate: The current study was approved by the Research Ethics Committee of Hospital Clínico San Carlos (22/474-O_M_NoSP) on July 21, 2022. In accordance with applicable ethical standards, the requirement for informed consent for participation was waived by the Ethics Committee (CEIm) due to the retrospective, non-interventional nature of the study and the use of pseudonymized data extracted from electronic medical records. The study involves minimal risk to participants, and obtaining consent was considered not reasonably practicable and would have imposed a disproportionate burden on patients with SPMS, as it would have required additional study‑related visits solely for consent purposes, potentially affecting participation and introducing selection bias. The waiver was granted in compliance with Regulation (EU) 2016/679 (GDPR) and Organic Law 3/2018 (LOPDGDD), ensuring full protection of personal data and confidentiality. Consent for publication: Not applicable. Author contributions: Celia Oreja-Guevara: Conceptualization; Investigation; Methodology; Resources; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing. Irene Gómez-Estévez: Investigation; Resources; Validation; Writing – review & editing. Laura Agüado García: Investigation; Resources; Validation; Writing – review & editing. Jesus Martín Martínez: Investigation; Resources; Validation; Writing – review & editing. Montserrat Gómez Gutiérrez: Investigation; Resources; Validation; Writing – review & editing. Francisco Gascón Giménez: Investigation; Resources; Validation; Writing – review & editing. Eduardo Agüera Morales: Investigation; Resources; Validation; Writing – review & editing. Virginia Meca-Lallana: Investigation; Resources; Validation; Writing – review & editing. Francisco Javier Barrero Hernández: Investigation; Resources; Validation; Writing – review & editing. Vicente González Quintanilla: Investigation; Resources; Validation; Writing – review & editing. Lucía Romero Pinel: Investigation; Resources; Validation; Writing – review & editing. Virginia Delgado Gil: Investigation; Resources; Validation; Writing – review & editing. Eduardo Durán Ferreras: Investigation; Resources; Validation; Writing – review & editing. Rosario Blasco Quílez: Investigation; Resources; Validation; Writing – review & editing. Jose Meca-Lallana: Investigation; Resources; Validation; Writing – review & editing. Lamberto Landete Pascual: Investigation; Resources; Validation; Writing – review & editing. Yolanda Aladro-Benito: Investigation; Resources; Validation; Writing – review & editing. Sabas Boyero Durán: Investigation; Resources; Validation; Writing – review & editing. Julia Gracia Gil: Investigation; Resources; Validation; Writing – review & editing. Ana Belén Caminero Rodríguez: Investigation; Resources; Validation; Writing – review & editing. Antonio Tomás Cano Orgaz: Investigation; Resources; Validation; Writing – review & editing. Sara Eichau Madueño: Investigation; Resources; Validation; Writing – review & editing. María Rosa Querol Pascual: Investigation; Resources; Validation; Writing – review & editing. María Otano Martínez: Investigation; Resources; Validation; Writing – review & editing. Ana María Alonso Torres: Investigation; Resources; Validation; Writing – review & editing. Carmen Calles Hernández: Investigation; Resources; Validation; Writing – review & editing. Ana López Real: Investigation; Resources; Validation; Writing – review & editing. Adrián Ares Luque: Investigation; Resources; Validation; Writing – review & editing. Jose Ramón Lorenzo González: Investigation; Resources; Validation; Writing – review & editing. Lidia Gómez Vicente: Conceptualization; Investigation; Methodology; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing. María Díaz Sánchez: Conceptualization; Investigation; Methodology; Resources; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The current study was funded by Novartis Farmacéutica S.A., Spain. C.O.-G. has received speaker and consultation fees from: Alexion, Biogen Idec, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva Pharmaceuticals. I.G.-E.: no disclosures reported. L.A.G. has received honoraria as consultant, speaker and/or received research support from Merck, Sanofi, Biogen, and Novartis. J.M.M. has received funding for research projects and fees for conferences, advice, and assistance for attendance at conferences from: Bayer, Biogen, Roche, Merck, Novartis, Janssen, and Sanofi. M.G.G. has received honoraria as speaker/meeting moderator/courses/symposium organized by Biogen Idec Inc., Bristol Myers Squibb, Janssen Pharmaceutical, Merck Serono, Mylan, Novartis Pharmaceutical, Roche, Sanofi Genzyme, and Bial. F.G.G. has received funding for research grants, travel support, and honoraria for speaking engagements from: Bayer, Biogen, Roche, Merck, Novartis, Almirall, Teva, Bristol-Myers-Squibb, Genzyme-Sanofi, and Janssen. E.A.M. has received speaker honoraria from: Roche, Novartis, Merck, Sanofi, and Biogen. V.M.L. has received consulting or speaking fees from: Almirall, Biogen, Genzyme, Janssen, Merck Serono, Novartis, Roche, Terumo, Sanofi, Teva Pharmaceuticals, Celgene, and Bristol Myers Squibb. F.J.B.H. has received compensation for consulting services and speaking honoraria from Almirall, Biogen, Bristol Myers Squibb, Genzyme, Johnson & Johnson, Merck, Novartis, Roche, Sanofi, and Teva. V.G.Q.: no disclosures reported. L.R.P. has received honoraria for participating on advisory boards and for collaborations as consultant and scientific communications, also received research support, travel, and congress expenses from Biogen Idec, Bristol Myers Squibb, Celgene, Horizon, Merck, Novartis, and Roche. V.D.G.: no disclosures reported. E.D.F. has received speaker and consultation fees from Almirall, Biogen Idec, Bristol Myers Squibb, Janssen, Mylan, Merck, Novartis, Roche, Sanofi Genzyme, and Teva Pharmaceuticals. R.B.Q.: no disclosures reported. J.M.L. has received honoraria as a consultant, as a chairman or lecturer in meetings, and has participated in clinical trials and other research projects promoted by Alexion, Almirall, Amgen, Biogen, Bristol-Myers-Squibb, Johnson & Johnson, Juvisé, Merck, Merz, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi, and UCB. L.L.P. has received honoraria as consultant, speaker and/or received research support from Almirall, Bayer, Biogen, Bristol Myers Squibb, Sanofi, Merck, Novartis, UCB Pharma, Roche, and Teva Pharmaceuticals. Y.A.-B. has received research grants, travel support, and lecturing and consulting fees from: Bayer, Biogen, Roche, Merck, Novartis, Almirall, Sanofi-Genzyme, Janssen, and Bristol Myers Squibb. S.B.D. has received research grants, travel support, or honoraria for speaking engagements from Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi Genzyme, and Teva Pharmaceuticals. J.G.G. has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from: Biogen, Merck, Sanofi, Roche, Teva Pharmaceuticals, Janssen, and Novartis; payment for expert testimony from: Roche and Sanofi; support for attending meetings and/or travel from: Biogen, Merck, Sanofi, Roche, Teva Pharmaceuticals, Janssen, Almirall, and Novartis; participation on a Data Safety Monitoring Board or Advisory Board: Sanofi. A.B.C.R. has received honoraria as speaker/meeting moderator/courses/symposium organized by Almirall Prodesfarma S.A, Biogen Idec Inc., Bristol Myers Squibb, Janssen Pharmaceutical, Merck Serono, Mylan, Novartis Pharmaceutical, Roche, Sanofi Genzyme, and Teva Pharmaceuticals; and for congress assistance from Biogen Idec Inc., Bial, Merck Serono, Novartis Pharmaceutical, Roche, Sanofi Genzyme, and Teva Pharmaceuticals. A.T.C.O. has received speaker honoraria from Novartis. S.E.M. has received speaker honoraria and consultant fees from: Janssen, Bristol-Meyers-Squibb, Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva Pharmaceuticals. M.R.Q.P. has received research support from Novartis. M.O.M. has received speaker honoraria and consultant fees from Novartis, Sanofi, Biogen, Roche, and Merck. A.M.A.T. has received consulting fees from: Novartis, Biogen, Janssen, Roche, and Sanofi; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from: Merck, Sanofi, Janssen, Almirall, Roche, Novartis, Biogen, and Bristol Myers Squibb; support for attending meetings and/or travel: Biogen. C.C.H. has received honoraria as consultant, speaker, and/or received research support from Teva Pharmaceuticals, Sanofi, Merck, Biogen, Bristol Myers, Roche, Novartis, Sandoz, Janssen, and Horizon. A.L.R. has acted as a speaker for Roche, Genzyme-Sanofi, Bristol Myers Squibb, Neuraxpharm, Merck Serono, and Novartis. A.A.L. has received speaker honoraria, consultant fees, and support to attend scientific meetings from Bayer, Biogen, Bristol, Janssen, Merck, Novartis, Roche, Sanofi, and Teva Pharmaceuticals. J.R.L.G.: no disclosures reported. L.G.V. is a Novartis employee. M.D.S. has received speaker honoraria and consultant fees from Novartis, Roche, Bristol, Biogen, Janssen, Sanofi, and Almirall. Availability of data and materials: Pseudonymized datasets and related documents, such as the statistical analysis plan, protocol, and amendments, can be shared upon reasonable request through a data sharing agreement. References Associated Data Supplementary Materials sj-docx-1-tan-10.1177_17562864261472650 – Supplemental material for Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study Supplemental material, sj-docx-1-tan-10.1177_17562864261472650 for Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study by Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduardo Durán Ferreras, Rosario Blasco Quílez, Jose Meca-Lallana, Lamberto Landete Pascual, Yolanda Aladro-Benito, Sabas Boyero Durán, Julia Gracia Gil, Ana Belén Caminero Rodríguez, Antonio Tomás Cano Orgaz, Sara Eichau Madueño, María Rosa Querol Pascual, María Otano Martínez, Ana María Alonso Torres, Carmen Calles Hernández, Ana López Real, Adrián Ares Luque, Jose Ramón Lorenzo González, Lidia Gómez Vicente and María Díaz Sánchez in Therapeutic Advances in Neurological Disorders